Complete the required fields to generate the oncology interpretation.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Use
Immunotherapy-adapted RECIST response assessment.
Section 2
Formula & Logic
Clinical Inputs
Percent change in target lesion sum
%
New lesion or PD threshold met
Binary clinical feature
Progression confirmed on subsequent scan
Binary clinical feature
Complete disappearance of disease
Binary clinical feature
Section 3
Pearls/Pitfalls
Result Bands
Section 4
Next Steps
Suggested Next Steps
01
Interpret the result in the full disease-specific clinical context.
02
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.
Section 5
Evidence Appraisal
Evidence Base
Immunotherapy-adapted RECIST response assessment.
OpiCalc Medical Oncology Module • Tumour Response Assessment. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.
Section 6
Literature
Context
iRECIST is included in the oncology module as a structured decision-support tool for tumour response assessment workflows.
